Jardiance and weight loss
Pro Research Analysisby 
Searched over 200M research papers
Jardiance (Empagliflozin) and Weight Loss in Type 2 Diabetes
SGLT2 Inhibitors and Weight Loss Benefits
Jardiance (empagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. Clinical studies consistently show that empagliflozin helps patients lose weight while improving blood sugar control. This weight loss effect is due to the drug’s ability to increase glucose excretion in urine, which leads to calorie loss and, consequently, a reduction in body weight Buysschaert2015Arun2022Wong2016+1 MORE.
Magnitude of Weight Loss with Jardiance
Empagliflozin has been shown to reduce body weight by approximately 2 kg in controlled trials lasting from 24 to 104 weeks. This weight loss is considered modest but consistent across studies, and it is an added benefit compared to some other diabetes medications that may cause weight gain Buysschaert2015Wong2016Scheen2015. The weight reduction is observed alongside improvements in blood sugar levels and blood pressure Buysschaert2015Scheen2015.
Comparison with Other Diabetes Medications
When compared to other diabetes treatments such as metformin, glimepiride, or sitagliptin, empagliflozin provides similar improvements in blood sugar control but with the added advantage of weight loss. Other medications, especially some older diabetes drugs, may not offer this benefit and can sometimes lead to weight gain Buysschaert2015Scheen2015.
Additional Health Benefits and Considerations
In addition to weight loss, empagliflozin has shown cardiovascular and kidney protective effects, making it a valuable option for patients with type 2 diabetes who are also at risk for heart or kidney problems Arun2022Scheen2015Xu2024. However, it is important to note that empagliflozin can increase the risk of mild urinary and genital infections, and there is a risk of diabetic ketoacidosis, especially around the time of surgery, so careful management is needed in these situations Buysschaert2015Scheen2015Xu2024.
Conclusion
Jardiance (empagliflozin) is effective for weight loss in people with type 2 diabetes, providing a modest but consistent reduction in body weight along with improved blood sugar control and additional heart and kidney benefits. These effects make it a strong option for patients who need both diabetes management and weight reduction, though potential side effects and perioperative risks should be considered.
Sources and full results
Most relevant research papers on this topic